CTIC 0.00 CTI BioPharma Corp.
| Range: | 4.01-9.1 | Vol Avg: | 5661603 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 0.83 | Cap: | 1.20B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Mar 21 1997 | Empoloyees: | 127 | ||
| CUSIP: | 12648L601 | CIK: | 0000891293 | ISIN: | US12648L6011 | Country: | US |
| CEO: | Dr. Adam R. Craig M.B.A., M.D., Ph.D. | Website: | https://www.ctibiopharma.com | ||||
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow